Circulating tumour DNA as a potential prognostic biomarker for immunotherapy

A study published in Nature Cancer showed that blood levels of DNA from solid tumours (circulating tumour DNA or ctDNA) were associated with the prognosis of cancer patients with different types of  tumours who had been treated with pembrolizumab. The study included 94 patients with various solid tumours who were treated with pembrolizumab. ctDNA levels varied […]

read more

CAR T cell therapy and renal cell carcinoma

In an interview with Targeted Oncology during the 2019 Kidney Cancer Research Summit, Dr Wayne Marasco, professor of medicine at Harvard Medical School, and principal investigator of cancer immunology and virology at Dana-Farber Cancer Institute, discussed engineering CAR T cells for the treatment of solid tumours, in particular renal cell carcinoma (RCC). It is hypothesised that […]

read more

Ilixadencel plus sunitinib combination for metastatic kidney cancer

A combination of ilixadencel plus sunitinib has shown a complete tumour response in patients with metastatic renal cell carcinoma (RCC) in a recent phase 2 clinical trial. Ilixadencel is an off-the-shelf immune primer for the treatment of solid tumours. The clinical trial assessed the effectiveness of combining ilixadencel with sunitinib in 88 untreated patients with […]

read more

Epacadostat plus pembrolizumab combination shows promise in advanced solid tumours

Headline results from the open-label phase I/II ECHO-202/KEYNOTE-037 trial assessing a combination of epacadostat plus pembrolizumab in 62 patients with advanced solid tumours shows objective responses in 12 of 22 patients (55%) with melanoma and in patients with other solid tumours, such as renal cell carcinoma (RCC). Severe and life-threatening side effects were reported by […]

read more

New immuno-oncology treatment to be tested in solid tumours

A new immuno-oncology treatment made by British company, Biotecnol, is about to be tested in early phase clinical trials for patients with advanced solid tumours, in collaboration with Cancer Research UK. The treatment, called Tb535H, is a T cell engager and the first to be developed by Biotecnol. Tb535H binds to 5T4/WAIF1, a protein found at the surface of tumour […]

read more
Showing all 5 results